Compare Pfizer Inc (PFE) vs Tesla, Inc. (TSLA) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Tesla's stock trades at $374.13, up 1.23% on the day, amid mixed technical signals with a bearish moving average trend but oversold RSI. Fundamentally, the company shows robust revenue near $95 billion for 2025 but faces margin compression, with net income down to $3.79 billion and elevated valuation ratios like a P/E of 347.64. Recent news highlights regulatory approval for self-driving software in Europe and a strategic pivot toward AI and robotics, offset by delivery misses and competitive pressures.

The outlook for Tesla hinges on execution in autonomous driving and energy segments, offering growth potential, but high valuation and margin risks warrant caution. Analyst consensus is divided with a $409.26 price target, reflecting optimism for innovation against near-term operational challenges and stock volatility.